Background: The ability of MDR Gram-negative bacteria to evade even antibiotics of last resort is a severe global challenge. The development pipeline for conventional antibiotics cannot address this issue, but antimicrobial peptides (AMPs) offer an alternative solution.
Introduction
The spread of antibiotic-resistant bacterial pathogens is a major challenge, with some strains now showing the worrying ability to overcome even antibiotics of last resort. [1] [2] [3] [4] The lack of antibiotics with novel targets or modes of action means that the development pipeline is insufficient to address MDR pathogens such as carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacteriaceae (CRE). 5, 6 Alternative treatment options include antibodies, probiotics and bacteriophages, 7 but antimicrobial peptides (AMPs) are especially promising due to their potent antimicrobial activity and their ability to neutralize toxins. 8, 9 Insects produce the largest and most diverse repertoire of AMPs, 10 and many insect AMPs have been assembled as a library of synthetic peptides. [11] [12] [13] [14] We previously described 23 AMPs from the medicinal maggots of the common green bottle fly Lucilia sericata, which colonizes habitats with remarkable microbial loads, such as carrion and infected wounds, and we tested these peptides against Escherichia coli and A. baumannii.
13,15
Here we report the characterization of LS-sarcotoxin and LSstomoxyn, two linear cationic AMPs from L. sericata, to assess their suitability as leads for systemic application in humans. Our experiments included in vitro and in vivo absorption, distribution, metabolism, excretion and toxicity (ADMET) analysis and activity profiling under physiological conditions against an extended panel of clinical MDR Gram-negative bacteria.
Materials and methods

Ethics
All procedures involving experimentation on animal subjects have been performed according to directive 63/2010 of the European Commission implemented in German animal welfare legislation and are registered by the competent authority (district government in Darmstadt, Hesse, Germany) under FH-1008. All procedures were in accordance with policies of Sanofi on the protection of animals and the responsible use of animals in research and production. 16, 17 Antimicrobial peptides LS-sarcotoxin and LS-stomoxyn and the corresponding D-enantiomers were produced by solid-phase synthesis at 90% purity (GenScript, USA). The amino acid sequences and calculated physicochemical properties are listed in Table 1 .
Bacterial isolates and culture conditions
The bacterial isolates (Tables S1 and S2 , available as Supplementary data at JAC Online) were predominantly cultured in CAMHB (Becton Dickinson, Germany). Clinical isolates were provided by the Robert Koch Institute (Wernigerode, Germany), originating from hospitalized patients in Germany (Table S2) .
Inhibition of microbial growth
MIC values were determined using initial cell populations and preparation methods appropriate for each test species (Supplementary Methods). MIC 50 and MIC 90 values (concentrations achieving no bacterial growth in 50%/90% of the tested isolates) were determined against a panel of MDR clinical isolates as previously defined. 18 
Chequerboard assay
Interactions between the peptides and colistin were investigated using the chequerboard assay, 19 which we adapted to 384-well microtitre plates with an assay volume of 20 lL. The fractional inhibitory concentration (FIC) values for each AMP and colistin were calculated for each combination using the equations FIC AMP " C AMP /MIC AMP and FIC CST " C CST /MIC CST , where MIC AMP and MIC CST are the MICs of LS-sarcotoxin/LS-stomoxyn and colistin, respectively, and C AMP and C CST are the concentrations of LS-sarcotoxin/LSstomoxyn and colistin in combination, respectively. 
Serial-passage mutagenesis
Serial-passage mutagenesis tests with E. coli and P. aeruginosa were conducted by a modification of the procedure described previously. 21 Briefly, 10-fold-concentrated 1:2 dilution series of the peptides were prepared in 384-well microtitre plates over a concentration range of 5210-0.16 lg/mL in a volume of 50 lL, and 2 lL aliquots were transferred to new 384-well microtitre plates. These plates were sealed and stored at -80 C until further use. On each assay day 18 lL of the desired bacterial suspension (5%10 5 cfu/mL) was added. After incubation for 23 h, the content of the wells containing the second highest peptide concentration allowing bacterial growth was diluted 1:10000 in fresh CAMHB, and 18 lL aliquots were added to new plates containing the 10-fold concentrated peptide dilution series. This passaging was repeated for 30 days consecutively.
Time-kill kinetics
LS-sarcotoxin and LS-stomoxyn were added at 1%, 2%, 4% and 8% MIC. 22 At time points 0, 0.5, 1, 2, 4 and 5 h after inoculation, 100 lL samples were diluted 1:10 in a 7-fold dilution series in PBS (pH 7.4) and plated on CAMHB agar using an Eddy Jet 2 (IUL, Spain). After overnight incubation at 37 C, the cultures were visualized using a Flash & Go camera (IUL) to determine the cfu/mL.
Haemolysis, cytotoxicity and potassium channel interaction assays
Haemolytic activity was assessed as previously described. 23 Cytotoxicity was determined by measuring intracellular ATP levels of mycoplasma-free HepG2 cells (ATCC) using the CellTiter-Glo ATP monitoring kit (Promega). 24 NOEC (no observed effect concentration) values were recorded, describing the highest peptide concentrations at which no cytotoxic effect (cell viability .80%) or precipitation of the test item was observed. AMPs were tested at concentrations of 1.56, 3.13, 6.25, 12.5, 25, 50, 100, 200 and 400 lM. AMP interaction with the human Ether-à-go-go-Related Gene (hERG) potassium channel was analysed using an automated patch-clamp method as previously described, 25 with AMPs at concentrations of 0.12, 0.37, 1.1, 3.3, 10 and 30 lM.
Metabolic stability and plasma clearance
The metabolic stability of the AMPs was determined by measuring the halflife in human hepatocytes and calculating the human extraction ratio based on intrinsic, scaled and predicted hepatic clearance (Supplementary Methods). 26 Scaled intrinsic hepatic clearance in humans was calculated based on a weight of 25.71 g liver/kg and a hepatocellularity of AMPs from a medical maggot JAC 99%10 6 cells/g liver. Scaled predicted hepatic clearance as well as the human extraction ratio were calculated based on a hepatic blood flow of 1.24 L/h/kg. 27 Plasma clearance was determined as previously described.
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Pharmacological off-target profiling
Pharmacological off-target profiling was conducted by CEREP (CelleLévescault, France) to investigate inhibitory effects against the targets specified in Figure S1 . All tests were conducted at a peptide concentration of 10 lM (42.0 and 43.3 mg/L for LS-sarcotoxin and LS-stomoxyn, respectively).
Handling of experimental mice
Six test-naive, healthy, 11-month-old, 34+4 g male mice (RjOrl:SWISS, Janvier, France) were separated into two groups after delivery and kept in specific pathogen-free (SPF) facilities (open polycarbonate cages, EU TYP III, 820 cm 2 ) on small animal litter composed of spruce granules (LIGNOCEL FS 14, cubic granulate, 3.5-4.5 mm). The housings were enriched with chew sticks (SAFE Block, SAFE, France), paper-based nesting material (SAFE crinklets, SAFE) and a mouse house/igloo. Each group of three animals was used as an experimental group in the study without any randomization. The mice were kept at 20-24 C, 45%-65% relative .128 The numbers of isolates for which the MIC value was determined are tabulated.
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humidity and a light/dark cycle of 12 h/12 h in group housings and supplied with tap water and V1534-10 mm pellets ad libitum.
Acute toxicity and mouse pharmacokinetics
The peptides were resolved in Ampura V R water (Fresenius, Germany) as stock solutions of 2.02+0.02 mg/g and each was administered as a single intravenous dose of 0.19+0.01 g through the tail vein to reach a final concentration of 10 mg/kg per mouse. Group . No control groups were used. All procedures were performed in laboratory H826-304 (Industriepark Höchst). After administration, the mice were routinely evaluated for signs of toxicity. At 0.08, 0.25, 0.5, 1, 2, 4, 8 and 24 h after administration, 10 lL blood samples were transferred to heparin-coated tubes and then into ethanol containing 0.5% (v/v) ammonia and the plasma proteins were precipitated for 20 min at 1735 g. Supernatants were separated and analysed in triplicate by LC-MS/MS (Supplementary Methods) to evaluate the stability of the parent peptides. Three mice per group were used to calculate the standard deviation and the coefficient of variation in pharmacokinetic studies. After the experiment, the mice were euthanized with CO 2 .
Results
Antimicrobial activity against reference strains LS-sarcotoxin and LS-stomoxyn lacked significant activity against Gram-positive bacteria and Candida albicans (MIC 1024 mg/L) as well as the Gram-negative bacterium Proteus mirabilis, which is intrinsically resistant to cationic peptides (Table S1) . 29, 30 However, both peptides showed strong activity (MIC 4 mg/L) against the tested Enterobacteriaceae and A. baumannii. Furthermore, when tested against P. aeruginosa, LS-stomoxyn was considerably more active (MIC 8 mg/L) than LS-sarcotoxin (MIC 64 mg/L; Table S1 ).
Activity against an extended panel of Gram-negative clinical isolates
Next, we tested the AMPs against 114 MDR clinical isolates, which were selected based on their resistance phenotype, including but not limited to resistance to colistin and meropenem (Table S2) . LSstomoxyn was further tested against 52 isolates of P. aeruginosa. LS-sarcotoxin was active in the range 2-16 mg/L against isolates of E. coli, Enterobacter spp., Klebsiella spp., Salmonella enterica, Citrobacter freundii and Acinetobacter spp., resulting in MIC 50 and MIC 90 values of 4 and 8 mg/L, respectively ( Table 2 ). The MIC profile of LS-stomoxyn ranged from 2 to .128 mg/L, with MIC 50 and MIC 90 values of 4 and 8 mg/L, respectively, except against K. pneumoniae (MIC 90 32 mg/L). The activity of LS-stomoxyn differed strikingly from that of LS-sarcotoxin by the comparably high activity against P. aeruginosa, with MIC values in the range 4-64 mg/L and MIC 50 , respectively, and MIC 90 values of 8 and 32 mg/L (Table 3 ). Both peptides were inactive or only weakly active (MIC 64 mg/L) against Stenotrophomonas maltophilia, Morganella morganii and Serratia fonticola, in accordance with previous findings, demonstrating that these species are intrinsically resistant to cationic peptides. 29, 30 To investigate potential correlation between colistin and/or meropenem resistance and a low susceptibility to the AMPs, we compared the signed-rank median MIC values of the two AMPs against the different resistance phenotypes (resistance to colistin and/or meropenem as well as isolates susceptible to both antibiotics) ( Figure S2 ). No significant differences in AMP activity were observed against resistant and susceptible isolates, although the activity of LS-stomoxyn against the colistin-resistant but meropenem-susceptible strains was less pronounced ( Figure S2 ).
Activity of all-D amino acid AMPs
To determine whether the AMPs recognize a specific target in a stereospecific manner or interact non-specifically with the lipid bilayer, [31] [32] [33] [34] [35] we tested the natural all-L and corresponding all-D enantiomers of both AMPs against several Gram-negative reference strains and clinical isolates ( Table 4 
Activity under physiological conditions
Physiological conditions were approximated by supplementing the CAMHB medium with 150 mM NaCl or 1.25 mM CaCl 2 . A saltdependent increase in MIC values was no higher than 2-fold in all experiments and there was little impact on the activity of LSsarcotoxin (Table 5 ). The addition of 10% (v/v) human serum boosted the antibacterial activity ( Table 5 ). The MIC values of LSsarcotoxin decreased by 8-to 32-fold, to 0.25 mg/L for E. coli, K. pneumoniae and A. baumannii, whereas the MIC values for LSstomoxyn decreased by 16-to 128-fold, to 0.063 mg/L. In contrast, the activity against P. aeruginosa declined by 2-to 4-fold. To replicate physiological conditions more accurately, we tested the peptides in CAMHB adjusted to 150 mM NaCl and also supplemented with 10% (v/v) human serum, which enhanced the activity of both AMPs even further ( Table 5 ). The MIC values of LSsarcotoxin against E. coli and A. baumannii were 128-fold lower (0.031 mg/L) and against K. pneumoniae and colistin-resistant E. coli they were 16-to 32-fold lower (0.13-1 mg/L). The MIC values of LS-stomoxyn were 0.016 mg/L for E. coli, K. pneumoniae and A. baumannii, reflecting at least a 256-fold increase in activity. A remarkable but less pronounced 64-fold increase in activity was also observed for the colistin-resistant E. coli and K. pneumoniae isolates. The addition of mouse serum rather than human serum achieved similar although somewhat less pronounced effects on the MIC values (Table S3) .
Antibacterial activity in combination with colistin
In preliminary experiments we observed 2-fold lower MIC values for LS-sarcotoxin and LS-stomoxyn when tested in the presence of sub-MIC concentrations of colistin (0.075 mg/L). For more detailed analysis, we performed chequerboard titration experiments ( Figure 1) . All experiments revealed a synergistic interaction between LS-sarcotoxin and colistin (FICI 0.5). No interaction was observed between LS-stomoxyn and colistin (FICI 1-0.6).
Development of resistance to L. sericata AMPs
Serial passaging of E. coli and P. aeruginosa for 30 days in the presence of LS-sarcotoxin or LS-stomoxyn did not result in the emergence of any resistant mutants ( Figure S3 ).
AMPs from a medical maggot JAC Time-kill kinetics LS-sarcotoxin at 2% and 3% the MIC led to a rapid 3 log reduction in cfu/mL after incubation for 1 h (Figure 2) . At a concentration corresponding to 8 % MIC, a 6 log reduction in cfu/mL was achieved after incubation for only 30 min. At 1 % MIC, LS-sarcotoxin reduced cfu/mL by 2.6 log after 1 h and did not achieve bactericidal activity. LS-stomoxyn was strongly bactericidal at all the concentrations we tested and caused a 3 log reduction after incubation for 1 h (Figure 2) .
In vitro toxicity studies
For LS-sarcotoxin, haemolysis was observed at 1024 mg/L, whereas all-D LS-sarcotoxin, LS-stomoxyn and all-D LS-stomoxyn showed The numbers of isolates for which the MIC value was determined are tabulated.
no haemolytic activity up to 1024 mg/L (Table 6 ). All four peptides showed minimal HepG2 toxicity, with NOECs of 100 lM (420 and 433 mg/L for LS-sarcotoxin and LS-stomoxyn, respectively; Table 6 ). Furthermore, as a model for cardiotoxicity, we investigated the effects of LS-sarcotoxin and LS-stomoxyn on the hERG potassium ion channel. No target-specific activity was observed at concentrations of up to 30 lM (126 and 130 mg/L, respectively), representing the highest test concentrations (Table 6 ).
In vitro stability studies
LS-sarcotoxin and all-D LS-sarcotoxin were stable, with half-lives .1000 min in human hepatocytes and calculated human extraction ratios ,14% (Table 6 ). LS-stomoxyn was less stable, with a half-life of 77 min and a calculated human extraction ratio of 68.8%. In contrast, all-D LS-stomoxyn was stable, with a half-life of 4110 min and a calculated human extraction ratio of 3.9%. All four peptides were considered unstable in human, mouse and rat Hirsch et al.
plasma after incubation for 24 h (Figure 3) . Only all-D LS-stomoxyn was stable in rat plasma (4% hydrolysis). LS-sarcotoxin and its all-D enantiomer were stable in human plasma for 1 h with only 17% and 14% loss, respectively.
Pharmacological off-target profiling
Pharmacological broad-spectrum off-target profiling of LSsarcotoxin and LS-stomoxyn against 19 G-protein-coupled receptors (GPCRs), 8 ion channels, 2 transporters and 4 enzymes Figure S1 ). We observed antagonistic inhibition of two human muscarinic acetylcholine receptors (M1 and M3) by LSstomoxyn, reducing their activity by 49% and 44%, respectively, and antagonistic inhibition of the human M3 receptor by LSsarcotoxin, reducing its activity by 31%.
Tolerability and mouse pharmacokinetic profiling
LS-sarcotoxin and LS-stomoxyn were each administered to 3/6 test-naive, healthy male Swiss mice at a single intravenous dose of 10 mg/kg. All mice survived without signs of toxicity or adverse events. Both peptides were rapidly cleared from the plasma. For LS-sarcotoxin, plasma concentrations above the lower limit of quantification (LLOQ) were only detected 5 min after administration, the first sampling timepoint (Figure 4a ). For LS-stomoxyn, plasma concentrations above the LLOQ were detected up to 15 min after administration (Figure 4b ).
Discussion
The selective activity of LS-sarcotoxin and LS-stomoxyn against Gram-negative bacteria was verified against a large panel of MDR clinical isolates, indicating the absence of cross-resistance to b-lactams, aminoglycosides, ciprofloxacin, chloramphenicol and sulfamerazine/trimethoprim. Selective activity against Gramnegative bacteria has been reported for other insect-derived AMPs 36,37 and artificial AMPs. 38 Among current clinical antibiotics, only colistin (polymyxin E) and polymyxin B display a similar activity profile, 39 highlighting the reportedly similar mechanism of polymyxins and cationic a-helical AMPs. 8, [40] [41] [42] [43] [44] We also observed results that highlighted differences between the L. sericata AMPs and polymyxins. For example, the AMPs retained full (LS-sarcotoxin) or only moderately reduced (LS-stomoxyn) activity against colistin-resistant isolates of E. coli, Enterobacter cloacae, K. pneumoniae and A. baumannii ( Figure S2) . Furthermore, the synergistic activity of LS-sarcotoxin with colistin would not be observable if both compounds had an identical target. Cationic AMPs from various sources are active against bacterial isolates with acquired colistin resistance, including AMPs isolated from frog skin, 45 cecropin A/melittin hybrid peptides, 46 the artificial peptides WLBU2 and WR12 47 and star-shaped peptide polymers composed of randomly polymerized lysine and valine residues, known as structurally nano-engineered antimicrobial peptide polymers (SNAPPs). 48 Other cationic AMPs, including human cathelicidin LL-37, 47 the insect cecropins A and B, 49 the porcine AMP cecropin PI 49 and the artificial tetra-branched peptide SET-M33L, 38 show cross-resistance to colistin. Whereas E. coli ATCC 25922 and P. aeruginosa ATCC 27853 rapidly develop resistance (.100-fold change in MIC) to colistin in serial passaging experiments, 50,51 we recovered no mutants resistant to LS-sarcotoxin or LS-stomoxyn during a 30 day passaging experiment at sub-MIC concentrations, also supporting a mode of action distinct from colistin.
Evidence for LS-sarcotoxin and LS-stomoxyn interacting with specific chiral targets rather than inducing detergent-like membrane lysis was provided by the low activity of their D-enantiomers. 34, 35, 52 Complete loss of activity was previously observed for the all-D analogue of apidaecin, a proline-rich AMP from honeybees, which was recently shown to bind specifically to the bacterial heat shock protein DnaK and to block the assembly of the 50S ribosomal subunit in a stereospecific manner. 53, 54 In contrast, the L and D forms of the ahelical AMPs cecropin A, cecropin B and magainin-2 showed nearly identical antibacterial activity, 31, 52, 55, 56 indicating that the formation of pores in lipid bilayers is sufficient. [31] [32] [33] [34] [35] 56 AMPs with a large hydrophobic surface area or a high cationic charge can be toxic to human cells, 57, 58 but neither LS-sarcotoxin nor LS-stomoxyn showed evidence of haemolytic or cytotoxic effects. AMPs are typically less active in the presence of human serum due to salt-mediated charge repulsion, proteolytic degradation or interactions with plasma proteins. [59] [60] [61] However, rather than the anticipated increase in MIC values, we observed a reduction for both peptides in the presence of human serum, as reported previously for polymyxin B, polymyxin B nonapeptide, colistin, magainin 2 and the synthetic polymyxin derivative SPR741, which may reflect interactions with the complement system. However, in preliminary experiments we also observed an increase in activity when we used serum in which the complement system was inactivated by heat treatment. Despite the increasing number of AMP candidates, 38, 51, 73, 74 toxicity and unfavourable ADMET properties 75, 76 have thus far prevented the development of AMPs for systemic application. 9, 74, 77 We found that LS-sarcotoxin and LS-stomoxyn were stable in the presence of hepatocytes (t1 =2 1060 and 77 min, respectively). Chemical analysis revealed the rapid loss of peptides exposed to human, mouse or rat plasma, but there was no difference in loss rate for the L and D forms, suggesting the AMPs are binding to plasma proteins such as albumin, apolipoproteins or glycoproteins. [78] [79] [80] [81] Although plasma protein binding of antibiotics affects pharmacological parameters, 75, [82] [83] [84] [85] [86] this does not rule out the suitability of the peptides for systemic application given that several approved antibiotics show .90% plasma protein binding. 64, 67, 68, 85, 87 In contrast to other reported AMPs, [88] [89] [90] LSsarcotoxin and LS-stomoxyn presented inconspicuous off-target profiles. Mouse tolerability studies revealed that LS-stomoxyn or LS-stomoxyn was well tolerated, indeed better tolerated than colistin, 38, 51, 91 which is approved for the clinic. [92] [93] [94] Although both peptides were rapidly cleared from mouse plasma and in vitro stability studies showed similar results for rat and human plasma, several strategies to increase the half-life of AMPs have been described, 38, 48, 60, 95 which could be used to improve the observed pharmacokinetic profiles.
In conclusion, both LS-sarcotoxin and LS-stomoxyn are promising leads for the development of new antibiotics with activity against MDR Gram-negative bacteria and possibly a novel mode of action. However, the pharmacokinetic properties of the native insect AMPs need to be improved before proceeding to in vivo infection models.
